KCNQ2 Membrane Protein Introduction

Introduction of KCNQ2

KCNQ2 is encoded by the KCNQ2 gene which is located on 20q13.3 in human. The molecular mass of KCNQ2 is about 95 kDa. It belongs to the potassium channel family, and the members of which are most wildly expressed ion channels. KCNQ2 can be found in the brain of adult and fetal. And it is mainly expressed in areas containing neuronal cell bodies. Besides, KCNQ2 can be phosphorylated and ubiquitinated, and both posttranslational modifications can influence the biological functions of KCNQ2 in vivo.

Basic Information of KCNQ2
Protein Name Potassium voltage-gated channel subfamily KQT member 2
Gene Name KCNQ2
Aliases KQT-like 2, Neuroblastoma-specific potassium channel subunit alpha KvLQT2, Voltage-gated potassium channel subunit Kv7.2
Organism Homo sapiens (Human)
UniProt ID O43526
Transmembrane Times Multi-pass membrane
Length (aa) 872

Function of KCNQ2 Membrane Protein

KCNQ2 can cooperate with another member of KQT (TC 1.A.1.15) subfamily to form a potassium channel of which characteristics are basically similar to the native M-current. At the same time, the current formed by KCNQ2 and KCNQ3 can be inhibited by linopirdine and XE991, and activated by anticonvulsant retigabine. So, KCNQ2 plays a very important role in regulating the excitability of the neurons. Beyond that, KCNQ2 participates in many other biological processes, such as chemical synaptic transmission, ankyrin binding and nervous system development. Accordingly, the mutations of KCNQ2 can cause seizures, benign familial neonatal 1 (BFNS1), and the patients with this disease will occur clusters of seizures in the first days of life. Other kinds of mutations in KCNQ2 are associated with epileptic encephalopathy, early infantile 7 (EIEE7) which is an autosomal dominant seizure disorder. Decreasing the KCNQ2 channel activity in GABAergic parvalbumin interneurons will render the SCZ-predisposing 22q11.2 deletion mice be less capable of inhibiting pyramidal neurons upon D2 modulation.

KCNQ2 transmembrane topology. Fig.1 KCNQ2 transmembrane topology. (Millichap, 2016)

Application of KCNQ2 Membrane Protein in Literature

  1. Choi S.J., et al. A Schizophrenia-Related Deletion Leads to KCNQ2-Dependent Abnormal Dopaminergic Modulation of Prefrontal Cortical Interneuron Activity. Cerebral Cortex. 2017, 1-17. PubMed ID: 28525574

    Accordingly, altered prefrontal cortex may function in schizophrenia (SCZ). Authors in this article find that KCNQ2 channel activity is an important factor in the modulation of prefrontal cortical interneuron activity.

  2. Millichap J.J., et al. KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients. Neurology Genetics. 2016, 2(5): e96. PubMed ID: 27602407

    In order to find out the relationship between KCNQ2 encephalopathy genotype and phenotype, authors in this article study 23 patients with the disease. They reveal that the mutations of KCNQ2 can cause neonatal-onset epileptic encephalopathy. And the channel activity of KCNQ2 is crucial in this disease.

  3. Orhan G., et al. Dominant-negative effects of\r, KCNQ2\r, mutations are associated with epileptic encephalopathy. Annals of Neurology. 2014, 75(3):382-394. PubMed ID: 24318194

    Authors in this article report 7 mutations of KCNQ2 and KCNQ3, all of which exhibit a clear loss of function. Children carrying 5 of the 7 KCNQ2 mutations suffer from severe epilepsy and cognitive decline. The phenome may relate to a dominant-negative reduction of the resulting potassium current at subthreshold membrane potentials.

  4. Reid E.S., et al. Seizures Due to a KCNQ2 Mutation: Treatment with Vitamin B6. JIMD Rep. 2016. PubMed ID: 26446091

    It has been suggested that vitamin B6 has a good effect on seizures in idiopathic epilepsy. Authors in this article report a de novo mutation (c.629G>A; p. Arg210His) in KCNQ2 through Whole-exome sequencing. And then, they reveal some potential mechanisms for the role of vitamin B6 in control seizures.

  5. Abidi A., et al. A recurrent KCNQ2 pore mutation causing early onset epileptic encephalopathy has a moderate effect on M current but alters subcellular localization of Kv7 channels. Neurobiology of Disease. 2015, 80:80-92. PubMed ID: 26007637

    It has been proved that mutations of KCNQ2 can cause either benign epilepsy or early-onset epileptic encephalopathy (EOEE). Authors in this article study 7 patients with the A294V mutation in KCNQ2. The result suggests that the disease severity is not only contributed by inhibiting M current but also by other mechanisms.

KCNQ2 Preparation Options

Based on the versatile Magic™ membrane protein production platform, Creative Biolabs can provide many flexible options for soluble and functional target protein, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-KCNQ2 antibody development services.

As a forward-looking biotech company as well as a leading customer service provider in the field of membrane protein, Creative Biolabs has won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects including generation of many functional membrane proteins. Please feel free to contact us for more information.


  1. Lee U S and Cui J. (2010). Bk channel activation: structural and functional insights. Trends in Neurosciences. 33(9): 0-423.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.

Online Inquiry

Verification code
Click image to refresh the verification code.


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us